Ligand validation:6WV3

OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6WV3_OLC_A_402	11%	38%	0.227	0.842	1.21	1.2	2	1	3	0	44%	0.44
6WV3_OLC_A_403	7%	69%	0.237	0.812	0.37	0.82	-	-	0	0	32%	0.32
6WV3_OLC_A_401	0%	5%	0.867	0.526	1.24	3.99	2	3	0	0	40%	0.38
6WVH_OLC_A_403	25%	77%	0.129	0.895	0.32	0.58	-	-	0	0	28%	0.2487
6WV6_OLC_A_401	15%	40%	0.202	0.838	1.09	1.23	2	1	2	0	60%	0.6
7Z0C_OLC_A_803	63%	52%	0.097	0.892	0.82	1.04	1	2	2	0	100%	1
4N6H_OLC_A_1222	63%	56%	0.117	0.932	0.81	0.87	1	1	0	0	88%	0.88
5IU4_OLC_A_2429	61%	59%	0.136	0.926	0.8	0.78	2	1	1	0	100%	1
6G7H_OLC_A_310	61%	92%	0.117	0.905	0.26	0.26	-	-	0	0	100%	1
7B0O_OLC_A_302	59%	54%	0.146	0.929	0.69	1.07	1	1	2	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.